bit.bio defends European patent for ‘novel’ opti-ox technology
The company secured claims to its iPSC-programming technology, deemed novel and inventive by the EPO.
Cytiva-Cell & Gene Therapy WP 2
Purespring secures $105m to start Phase I/II trial of IgAN gene therapy
Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m
GC Therapeutics secures $65m to launch into off-the-shelf iPSC therapy space
ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific
ProKidney drops Phase III CKD study to focus on US market and save up to $175m
Skyline wins orphan drug designation for retinitis pigmentosa gene therapy
CRISPR-based Casgevy is made accessible in England following NICE guidance
